Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug:170:105711.
doi: 10.1016/j.phrs.2021.105711. Epub 2021 Jun 3.

Remdesivir in moderate to severe COVID-19: A matter of time?

Cecilia Bonazzetti  1 , Andrea Giacomelli  2 , Martina Pavia  3 , Chiara Fusetti  2 , Martina Gerbi  2 , Francesco Petri  2 , Andrea Poloni  2 , Letizia Oreni  4 , Anna Lisa Ridolfo  4 , Spinello Antinori  2
Affiliations
Comment

Remdesivir in moderate to severe COVID-19: A matter of time?

Cecilia Bonazzetti et al. Pharmacol Res. 2021 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. Giacomelli received funding from consultancy fees from Mylan and educational support from Gilead. Dr. Antinori has received support for research activities from Pfizer and Merck Sharp & Dome. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Comment on

References

    1. Giacomelli A., Pagani G., Ridolfo A.L., Oreni L., Conti F., Pezzati L., Bradanini L., Casalini G., Bassoli C., Morena V., Passerini S., Rizzardini G., Cogliati C., Ceriani E., Colombo R., Rusconi S., Gervasoni C., Cattaneo D., Antinori S., Galli M. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study. J. Med. Virol. 2021;93(3):1421–1427. - PMC - PubMed
    1. Antinori S., Cossu M.V., Ridolfo A.L., Rech R., Bonazzetti C., Pagani G., Gubertini G., Coen M., Magni C., Castelli A., Borghi B., Colombo R., Giorgi R., Angeli E., Mileto D., Milazzo L., Vimercati S., Pellicciotta M., Corbellino M., Torre A., Rusconi S., Oreni L., Gismondo M.R., Giacomelli A., Meroni L., Rizzardini G., Galli M. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status. Pharmacol. Res. 2020;158 - PMC - PubMed
    1. Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., Lopez de Castilla D., Finberg R.W., Dierberg K., Tapson V., Hsieh L., Patterson T.F., Paredes R., Sweeney D.A., Short W.R., Touloumi G., Lye D.C., Ohmagari N., Oh M., Ruiz-Palacios G.M., Benfield T., Fätkenheuer G., Kortepeter M.G., Atmar R.L., Creech C.B., Lundgren J., Babiker A.G., Pett S., Neaton J.D., Burgess T.H., Bonnett T., Green M., Makowski M., Osinusi A., Nayak S., Lane H.C. ACTT-1 study group members. remdesivir for the treatment of Covid-19 – final report. N. Engl. J. Med. 2020;383(19):1813–1826. - PMC - PubMed
    1. Wang Y., Zhang D., Du G., Du R., Zhao J., Jin Y., Fu S., Gao L., Cheng Z., Lu Q., Hu Y., Luo G., Wang K., Lu Y., Li H., Wang S., Ruan S., Yang C., Mei C., Wang Y., Ding D., Wu F., Tang X., Ye X., Ye Y., Liu B., Yang J., Yin W., Wang A., Fan G., Zhou F., Liu Z., Gu X., Xu J., Shang L., Zhang Y., Cao L., Guo T., Wan Y., Qin H., Jiang Y., Jaki T., Hayden F.G., Horby P.W., Cao B., Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. - PMC - PubMed
    1. 〈https://www.aifa.gov.it/documents/20142/1123276/remdesivir_update01_24.1...〉. (Accessed 21 May 2021).